EyePoint Announces Participation at Upcoming Investor Conferences
Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 1:25 p.m. ET
Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Tuesday, June 10, 2025Time: 2:40 p.m. ET
Guggenheim BioFrontier Boston EventDate: Wednesday, June 25, 2025Time: 4:00 p.m. ET
A live webcast and subsequent archived replay of each fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema.
The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts, and operates a commercial-scale manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni LuFTI Consulting Direct: 203-722-8743 / 667-321-6018tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
a few seconds ago
More shrimp recalled due to possible radioactive contamination, FDA says
Multiple brands of raw and cooked frozen shrimp have been added to an ongoing recall of frozen shrimp due to possible radioactive contamination, according to the Food and Drug Administration. The frozen shrimp products are sold by Southwind Foods, LLC, of Carson, California, according to an FDA alert issued on Thursday. In a company announcement released by the FDA, Southwind Foods said it is "voluntarily recalling a limited quantity of frozen shrimp" due to the possible contamination with Cesium-137, a radioactive isotope. The bagged, frozen raw and cooked shrimp from the latest recall were sold between July 17 and Aug. 8 in nine states -- Alabama, Arizona, California, Massachusetts, Minnesota, Pennsylvania, Utah, Virginia and West Virginia -- the FDA said. The products were sold under the brand names Sand Bar, Arctic Shores, Best Yet, Great American and First Street, according to the recall notice. No illnesses have been reported to date, the company said. The products are being recalled after raw frozen shrimp sold by Great Value at Walmart was similarly recalled earlier this week due to possible contamination with Cesium-137. Both the recalled Great Value and Southwind Foods products were packaged in Indonesia by BMS Foods, according to the FDA. The FDA said it determined that the shrimp from BMS Foods violates the Federal Food, Drug, & Cosmetic Act in that "it appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern." Products from BMS Foods will no longer be imported into the U.S. "until the firm has resolved the conditions that gave rise to the appearance of the violation," the FDA said. At this time, no product that has tested positive or alerted for Cesium-137 has entered the U.S. food supply, the FDA said. The FDA said it will "continue working with industry to trace all implicated products processed" by BMS Foods, "to gather as much information about them as possible and take action as appropriate." Cesium is a soft, flexible, silvery-white metal that becomes liquid near room temperature, but easily bonds with chlorides to create a crystalline powder, according to the U.S. Environmental Protection Agency. External exposure to large amounts of Cesium-137, according to the EPA, can cause burns, acute radiation sickness and even death.
Bloomberg
a few seconds ago
- Bloomberg
Zip Shares Soar in Sydney After Mulling Nasdaq Dual-Listing Plan
Zip Co. shares jumped as much as 24% on Friday after the Australian digital payments platform said it was considering a dual listing on the Nasdaq, as part of its push to expand in its key growth market. Shares popped the most the most since April 10 in early Sydney trading. Zip intends to maintain its primary listing on the Australian Securities Exchange, the company said in a statement on Friday.
Business Wire
29 minutes ago
- Business Wire
Avnet Increases Quarterly Dividend by 6%
PHOENIX--(BUSINESS WIRE)--Avnet, Inc. (Nasdaq: AVT), a leading global technology solutions provider, announced that its Board of Directors has approved a 6% increase in the quarterly cash dividend to $0.35 per share. The dividend will be paid on September 26, 2025, to shareholders of record as of the close of business on September 17, 2025. 'The dividend increase is a reflection of the Board's confidence in our financial position,' said Phil Gallagher, Avnet's Chief Executive Officer. 'Avnet is generating strong operating cash flow, which enables us to return value to our shareholders while delivering on our long-term growth strategy.' About Avnet As a leading global technology distributor and solutions provider, Avnet has served customers' evolving needs for more than a century. Through regional and specialized businesses around the world, we support customers and suppliers at every stage of the product lifecycle. We help companies adapt to change and accelerate the design and supply stages of product development. With a unique viewpoint from the center of the technology value chain, Avnet is a trusted partner that solves complex design and supply chain issues so customers can realize revenue faster. Learn more about Avnet at (AVT_IR) Visit the Avnet Investor Relations website at or contact us at investorrelations@
